AC Immune SA

As of June 30, 2026, AC Immune SA carries a market capitalization of 207.80M, placing it among publicly traded companies globally. Its enterprise value stands at 130.60M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

AC Immune SA's next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, AC Immune SA has 99.43M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 10.79, and the price-to-book ratio stands at 5.45.

These figures are as of June 30, 2026. The EV/Sales ratio of 6.88 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 130.60M versus a market cap of 207.80M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, AC Immune SA maintains a current ratio of 0.93, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 11.66, indicating elevated leverage, while an interest coverage ratio of -200.41 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, AC Immune SA posted a negative return on equity (ROE) of -78.53, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -25.34, reflecting losses generated across the asset base. The company generates approximately 141,050.95 in revenue per employee across its workforce of 134.50, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, AC Immune SA's stock has declined approximately 4.56% over the past 52 weeks. The 50-day moving average sits at 2.32, while the 200-day moving average is 2.38.

Over the twelve months ended June 30, 2026, AC Immune SA generated 18.97M in revenue and converted that into -46.76M in net income, yielding earnings per share of -0.48. EBITDA reached -46.47M, while operating income came in at -47.35M.

As of June 30, 2026, AC Immune SA holds 81.65M in cash and equivalents against 4.44M in total debt, resulting in a net debt position of -30.08M. Total book value stands at 38.11M, with working capital of -7.41M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The operating margin of -249.59 and net profit margin of -246.49 provide insight into operational efficiency.

As of June 30, 2026, AC Immune SA has an Altman Z-Score of -6.66, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.